跳至主要内容
临床试验/NCT07212595
NCT07212595招募中2 期

Biomarker and Renal Angina Validation to Assess Heart-Kidney Outcomes After Amino Acid Therapy

Dana Fuhrman1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2026年7月8日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
30
试验地点
1
主要终点
Rate of acute kidney injury on post-operative days 2, 3, or 4

研究概览

简要总结

The goal of the BRAVE-HEART study is to learn if an amino acid infusion can reduce the risk of developing acute kidney injury after cardiac surgery in children. The main questions it aims to answer are:

  1. Does an amino acid infusion decrease the number of participants with acute kidney injury?
  2. Does an amino acid infusion decrease the number of days that participants are on a ventilator after cardiac surgery?

Researchers will compare amino acids to a placebo (a look-alike substance that contains no drug) to see if amino acids decrease the number of participants with acute kidney injury.

Participants will receive an amino acid or placebo infusion for up to 72 hours starting during cardiac surgery and only while in the operating room or the intensive care unit.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
— 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Expected to be at high risk of developing acute kidney injury after cardiac surgery based on Age, The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery (STAT) score, and anticipated cardiopulmonary bypass time
  • Age less than or equal to 18 years
  • Weight greater than or equal to 5 kilograms

排除标准

  • Preoperative extracorporeal organ support
  • History of chronic kidney disease
  • Known or suspected inborn errors of amino acid metabolism
  • Known hypersensitivity to amino acids
  • Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) > 3 times the upper limit of normal for age/gender
  • Preterm infants less than 6 months of age who were born at less than 36 weeks gestational age
  • Anuria at the time of randomization
  • Expected use of total parental nutrition (TPN) within the first 72 hours post-operatively

研究组 & 干预措施

Placebo Infusion

Placebo Comparator

Placebo Infusion for up to 72 hours

干预措施: Lactated ringers solution (Drug)

Acid Acid Infusion

Experimental

Amino Acid Infusion for up to 72 hours

干预措施: Amino Acid infusion (Drug)

结局指标

主要结局

Rate of acute kidney injury on post-operative days 2, 3, or 4

时间窗: From enrollment to post-operative day 4

The rate of participants randomized to the amino acid infusion developing acute kidney injury as defined by Kidney Disease Improving Global Outcomes (KDIGO) as Stage 1, 2, or 3 will be compared to the rate of acute kidney injury in the placebo group

Rate of mechanical ventilation at 96 hours post-operatively

时间窗: From enrollment to 96 hours post-operatively

Rate of participants randomized to the amino acid infusion needing invasive mechanical ventilation beyond 96 hours post-operatively from congenital cardiac surgery repair will be compared to the rate from the placebo group.

次要结局

未报告次要终点

研究者

发起方
Dana Fuhrman
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Dana Fuhrman

Associate Director, Center for Acute Care Nephrology

Children's Hospital Medical Center, Cincinnati

研究点 (1)

Loading locations...

相似试验